Drugpatentwatch

Employees 4 Updated 2026-02-10
Rank trajectory2024-02 → 2026-05 · 28 months
CLIMBED +141From #503 (2024-02) to #362 today
#329#381#433#485#5372024-02: #5032024-03: #5072024-04: #4612024-05: #4532024-06: #4602024-07: #5102024-08: #5102024-09: #5022024-10: #5072024-11: #5102024-12: #5112025-01: #5122025-02: #5102025-03: #5132025-04: #4722025-05: #4722025-06: #4152025-07: #4062025-08: #3542025-09: #3612025-10: #3652025-11: #3612025-12: #3542026-01: #3532026-02: #3542026-03: #3622026-04: #3642026-05: #362 #362 now Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26May 26

How this is computed · one composite score, recomputed across all 28 months, ranked on a 3-month moving average

What it is

DrugPatentWatch is thinkBiotech’s long-running pharmaceutical patent intelligence platform, and the strongest public evidence places it squarely in loss-of-exclusivity and generic-entry decision support rather than generic IP administration. The product combines Orange Book and Purple Book patent links, regulatory protections, patent litigation, pricing, sales, and supplier data into a drug-centric research workflow. The clearest practitioner jobs are fivefold. First, pharma legal, BD, and commercial teams use it when nobody agrees on the real loss-of-exclusivity date because patent terms, exclusivities, settlements, and litigation milestones point in different directions. Second, generic challengers and outside counsel use it to decide whether a Paragraph IV or related entry strategy has a real path through the thicket of secondary patents, manufacturing claims, and prior settlements. Third, analysts use it to monitor patent and litigation changes with daily updates and custom alerts instead of checking FDA, court, and patent sources manually. Fourth, global patent and prior-art style searches matter because the product links active and expired drug patents across 134 countries and highlights expired or abandoned rights. Fifth, the platform is positioned for broader market-entry and competitive-intelligence work, including API sourcing, biosimilar tracking, and market share forecasting. Public pricing is unusually transparent for this niche: starter and professional plans are listed, along with a custom enterprise tier. The tradeoff is that the site is marketing-heavy, the policy pages appear stale, and I did not find public security documentation strong enough to verify enterprise claims beyond SSL, privacy-policy language, and a pricing-page promise of a privacy-centric architecture.

Capabilities

Spans 6 product areas: Intellectual Property Practice, Legal Research, Litigation , Analytics, Data , Visualization.

Workflow Coverage

Based on published feature listings, this tool maps to 3 workflow areas:

  • Research & Analysis — Citation Checking
  • Document Drafting & Automation
  • Filing & Compliance

Workflow mappings derived from published feature lists. Not independently verified.

What We Haven’t Verified

This page was assembled from publicly available information. Feature claims and workflow mappings are based on what the vendor and third-party listings publish — not hands-on testing or practitioner feedback.

Integrations

Platforms Drugpatentwatch integrates with. Depth — where curated — reflects how native the connection is. Uncurated entries render without a depth dot.

Deep — bi-directional API Medium — one-way sync / webhook Shallow — middleware / Zapier-class

Community ratings
Alternatives

Other IP Management vendors in the directory. "Compare" pages are editorial and coming as we build them.

Founders
Webinars

We haven't found any webinars offered by Drugpatentwatch yet — see all legal tech webinars.

Events to see Drugpatentwatch at

No upcoming event presence found — browse all events.